Back to School: How biopharma can reboot drug development. Access exclusive analysis here

RGN-137: Phase II data

Molecular target: Not applicable

Description: Topical formulation of synthetic thymosin beta 4 (TB4), a naturally occurring 43-amino acid peptide

Indication: Treat epidermolysis bullosa

Endpoint: Safety; time to complete

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE